Clinical Trial

HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)

Study acronym: HOBSCOTCH-CA
Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the ability of the home-based intervention, HOBSCOTCH-CA, to improve the quality of life and cognitive function in Service Members, Veterans and civilians who are survivors of brain cancer or a brain tumor (CA participants). This study will also assess the ability of the HOBSCOTCH-CA program to improve quality of life in caregivers of patients with brain cancer/tumor and to reduce caregiver burden. Enrolling with a Caregiver is optional for CA participants. Investigators will compare two groups of CA participants and their Caregiver (enrolling with a Caregiver is optional): one who receives HOBSCOCTCH-CA immediately (Group 1) and another group that will receive HOBSCOTCH-CA (Group 2) after a 3-month waiting period. Participants will be in the study for about 6 months total. HOBSCOTCH-CA involves 45 to 60 minute one on one virtual sessions with a certified Cognitive Coach including a "pre" program session and 8 weekly sessions thereafter. Participants will learn about problem solving therapy and mindfulness or relaxation training. CA participants are asked to do short homework assignments and keep a brief daily diary on a smart phone app. All participants complete study questionnaires or surveys at enrollment, 3 months later and at 6 months (at the end of the study).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-04-09; most recent amendment 2025-11-18.
Status change: Not Yet Recruiting → Recruiting 2025-09-22
Trial Details
NCT Number NCT06930846
Lead Sponsor Dartmouth-Hitchcock Medical Center
Collaborators: Congressionally Directed Medical Research Programs, Mayo Clinic, University of North Carolina, Dartmouth College
Conditions Brain Cancer, Brain Tumor, Brain Neoplasms, Primary Brain Tumor, Low-grade Glioma, Oligodendroglioma, Meningioma, Low Grade Astrocytoma +4 more
Enrollment 125 participants
Start Date 2025-11-03
Primary Completion 2028-07 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-11-21